Tagged with M

Canada Matthieu Grosfils, general manager of the Canadian affiliate of Laboratoires Expanscience, a European leader in dermocosmetics, discusses the significance behind the establishment of the affiliate in 2015, the strengths of the company’s flagship Mustela® line, and his strategic priorities for the future growth of the affiliate. You joined Laboratoires Expanscience…

Tunisia Sara Masmoudi, general manager at Teriak, one of Tunisia’s top three pharmaceutical companies, sums up the evolution the company has undergone since she took over its direction in 2003 at age 32. She also talks about the recent acquisition Teriak has made of Cinpharm, a Cameroonian manufacturer, in line with…

Tunisia Diabetes is an important problem in Tunisia, with prevalence is expected to increase over the coming years. Jean-Francois Courtet, general manager of Novo Nordisk in Tunisia, points out rgar “diabetes is the second largest cause of death in Tunisia”. Moez Lindhallah Mokadem, director of Pharmacie Centrale de Tunisie (PCT), adds…

India At the Organization of Pharmaceuticals Producers of India (OPPI), the association representing the research-based pharmaceutical companies in India, putting the patient at the center of all that they do is part of their DNA. On the occasion of their 51st Annual Day celebrations, experts met to discuss the need to…

Tunisia Ridha Charfeddine, founding CEO of Unimed and president of the National Chamber of the Pharmaceutical Industry (CNIP) discusses enforcing European quality standards in Tunisia, the CNIP’s role in guiding pharmaceutical and medical device companies in Tunisia, as well as his entrepreneurial journey with Unimed, now the preferred partner of the…

Bulgaria Urszula Orzel, general manager at MSD Bulgaria, explains how the affiliate has become one of the fastest growing players in the country and emphasizes that pharmaceutical companies are not merely manufacturers of drugs, but should also be socially committed. This is your first time as a country manager. How did…

Tunisia Ramzi Lebbi, general director and co-founder of mc PHARMA, a Tunisian medical information and promotion agency, describes the company’s evolution since its foundation 15 years ago, its service provider activities for multinational companies, and the potential expansion of its portfolio of services. Mr. Lebbi, looking back at mc PHARMA’s creation,…

Tunisia Ali Achouri of Laboratoires Generika in Tunisia discusses his success story, his attentiveness to the satisfaction of its customers, the importance of geographical and cultural proximity with pharmaceutical companies in Maghreb, and how Generika will soon offer its services for the production of inhalable dosage forms as well as various…

Switzerland Thierry Mauvernay, president and delegate of the board of Debiopharm, discusses the Swiss Group’s development over its 38 years of history, its unique business strategy, and how new trends such as personalized medicine and digitalization are being embraced moving forward.   Our goal is not to become much bigger, but…

Austria Barbara Rangetiner and Josef Weinberger of the Austrian affiliate of Octapharma, the largest privately owned human protein products manufacturer in the world, discuss the strategic significance of Austria to the group, the nation’s historical excellence in plasma and hematology, and recent upgrades to the affiliate’s manufacturing and fractionation capabilities Vienna…

Tunisia Walid Lakhdar, country business unit head for Tunisia and Libya at Pfizer, stresses the company’s ongoing dedication to patients in Tunisia. This was illustrated by the significant investments Pfizer has made in Tunisia after the revolution and still continues to make. Lakhdar talks about Pfizer’s successful partnerships in the country…

Austria Dr. Wolfgang Harrer, regional manager of Chiesi Central and Eastern Europe (CEE), discusses the challenges of managing the region’s diverse cultural differences and the importance of CEE within global operations. Furthermore, he points out the factors influencing the influx of innovative drugs into Austria, especially in rare diseases, and highlights…